All In MedTech

FDA Clearance Tracker · P220029-S001

Optilume™ BPH Catheter System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 25, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 25, 2023

Approved

Time to decision

29 days

Received Jul 27, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P220029-S001
Device name
Optilume™ BPH Catheter System
Applicant location
Minneapolis, MN
Received
Jul 27, 2023
Decided
Aug 25, 2023
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P220029

Device type

Device class
Class III

Every decision under product code QXB

FDA's approval statement

As written in FDA's record.

Approval of the protocol for the post-approval study (PAS) protocol.

Source documents

Other decisions for Urotronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.